文献速递妇科产科

绝经激素治疗后的死亡模式:一项基于人群队列的长期随访

Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort.
PubMed 文献 · BJOG · 2018-09-19

丹麦基于饮食、癌症与健康队列的29 243名50-64岁女性前瞻性随访至2013年12月31日,中位随访17.6年。调整生活方式危险因素后,激素使用与全因死亡率无关;基线使用者心血管病死亡率仅在随访5年后较低(HR 0.54;95%CI 0.32-0.92),结直肠癌死亡率仅在15年后较低(HR 0.64;95%CI 0.46-0.89),乳腺癌死亡率仅在15年后较高(HR 1.34;95%CI 1.05-1.72)。

要点

  • 激素使用与全因死亡率无关,与激素方案无关。
  • 基线使用者心血管病死亡率仅在随访5年后较低(HR 0.54;95%CI 0.32-0.92),随后消失。
  • 基线使用者结直肠癌死亡率仅在15年后较低(HR 0.64;95%CI 0.46-0.89),乳腺癌死亡率仅在15年后较高(HR 1.34;95%CI 1.05-1.72)。

核心结论

  • 中年女性绝经期使用激素与总体死亡率无关,病因别死亡率存在显著但较弱的差异,且随时间变化,决策时需仔细权衡个体风险与治疗时长。

研究设计与样本

  • 基于人群的前瞻性队列研究,纳入1993-97年入组的饮食、癌症与健康队列中29 243名50-64岁女性,随访至2013年12月31日。
  • 采用Cox比例风险模型,按基线激素使用情况并调整相关潜在混杂因素,分析不同随访时长的死亡模式。
  • 结局信息来自丹麦死因登记, linkage 99.6%。

主要发现

  • 中位随访17.6年期间共4098名女性死亡。
  • 调整相关生活方式危险因素后,激素使用与全因死亡率无关,与激素方案无关。
  • 基线使用者心血管病死亡率仅在随访5年后较低(HR 0.54;95%CI 0.32-0.92),随随访延长而消失。
  • 基线使用者结直肠癌死亡率仅在随访15年后较低(HR 0.64;95%CI 0.46-0.89),乳腺癌死亡率仅在随访15年后较高(HR 1.34;95%CI 1.05-1.72)。
  • 其他类型癌症死亡率及卒中死亡率均无显著关联。

临床怎么用

  • 原文结论指出,决策激素治疗时需仔细考虑个体风险和治疗时长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate long-term pattern of mortality in menopausal women according to different modalities of hormone therapy. DESIGN: Population-based prospective cohort study. SETTING: Denmark 1993-2013. POPULATION: A total of 29 243 women aged 50-64 years at entry into the Diet, Cancer and Health Cohort, enrolled 1993-97 and followed through 31 December 2013. METHODS: Cox' proportional hazards models for increasingly longer periods of follow-up time were used to estimate mortality pattern according to baseline hormone use adjusted for relevant potential confounders. MAIN OUTCOME(S): All-cause and cause-specific mortality. Outcome information was obtained from the Danish Register of Causes of Death (linkage 99.6%). RESULTS: A total of 4098 women died during a median follow up of 17.6 years. After adjustment for relevant lifestyle risk factors, hormone use had no impact on all-cause mortality, regardless of modality. Among baseline users, lower cardiovascluar disease mortality was only evident after 5 years [hazard ratio (HR) 0.54; 95% CI 0.32-0.92], but dissipated with additional follow up. Conversely, lower colorectal cancer mortality (HR 0.64; 95% CI 0.46-0.89) and higher breast cancer mortality (HR 1.34; 95% CI 1.05-1.72) only became evident after 15 years of follow up. There were no significant associations for mortality from other types of cancer or from stroke. CONCLUSIONS: In this long-term follow-up study, taking hormones during menopause was not associated with overall mortality among middle-aged women. Investigating cause-specific mortality revealed significant, albeit weak, differential associations according to both causes of death and over time, underlining the importance of carefully considering individual risks and duration of treatment when making decisions on hormone therapy. TWEETABLE ABSTRACT: Long-term follow-up study confirms no association between menopausal hormone therapy and overall mortality.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Holm M, Olsen A, Au Yeung SL, et al. Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort. BJOG. 2018. PMID: 30106241. doi:10.1111/1471-0528.15433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。